Related Experiment Video
Updated: May 22, 2025

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
Roluperidone monotherapy, a treatment for negative symptoms in schizophrenia
Michael Davidson1,2, Nadine Noel3, Florent Schmitt3
1Minerva Neurosciences, 1500 District Avenue Burlington, MA 01803, USA.
Abstract:
Roluperidone is a drug in development targeting primary negative symptoms in schizophrenia, which binds sigma-2, 5-HT2A, and alpha1a receptors. Roluperidone administered as monotherapy to patients suffering from mild to moderate negative symptoms and withdrawal from antipsychotic drugs, improved negative symptoms in 2 clinical trials. The patients who were symptomatically stable for 3 or 6 months before antipsychotic drug withdrawal showed a very low rate of psychotic symptoms worsening over 6 or 9-month trial duration. Focus: Treatment of primary negative symptoms in a subgroup of patients suffering from schizophrenia.
Related Concept Videos
Drug Therapy
Antianxiety Medications
Psychosis: Goals of Pharmacotherapy
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Negative and Cognitive Symptoms of Schizophrenia
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Antidepressant Drugs: MAOIs and Other Agents
Psychosis and Antipsychotic Drugs: Overview

